Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01228396 (ClinicalTrials.gov)	May 2009	26/9/2010	AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis	A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Drug: Hyperimmune caprine serum against HIV lysate	Daval International Limited	NULL	Active, not recruiting	18 Years	N/A	Both	20	Phase 2	United Kingdom
2	EUCTR2006-006872-39-GB (EUCTR)	04/01/2008	19/06/2007	A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function	A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function	Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis MedDRA version: 9.1;Classification code 10059617;Term: Overactive bladder MedDRA version: 9.1;Classification code 10012547;Term: Detrusor hyperreflexia	Product Name: AIMSPRO	Daval International Limited	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):	United Kingdom